Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 12;22(4):1823.
doi: 10.3390/ijms22041823.

Role of the Macrophage Migration Inhibitory Factor in the Pathophysiology of Pre-Eclampsia

Affiliations
Review

Role of the Macrophage Migration Inhibitory Factor in the Pathophysiology of Pre-Eclampsia

Tullia Todros et al. Int J Mol Sci. .

Abstract

Proinflammatory cytokines are produced in pregnancy in response to the invading pathogens and/or nonmicrobial causes such as damage-associated molecules and embryonic semi-allogenic antigens. While inflammation is essential for a successful pregnancy, an excessive inflammatory response is implicated in several pathologies including pre-eclampsia (PE). This review focuses on the proinflammatory cytokine macrophage migration inhibitory factor (MIF), a critical regulator of the innate immune response and a major player of processes allowing normal placental development. PE is a severe pregnancy-related syndrome characterized by exaggerated inflammatory response and generalized endothelial damage. In some cases, usually of early onset, it originates from a maldevelopment of the placenta, and is associated with intrauterine growth restriction (IUGR) (placental PE). In other cases, usually of late onset, pre-pregnancy maternal diseases represent risk factors for the development of the disease (maternal PE). Available data suggest that low MIF production in early pregnancy could contribute to the abnormal placentation. The resulting placental hypoxia in later pregnancy could produce high release of MIF in maternal serum typical of placental PE. More studies are needed to understand the role of MIF, if any, in maternal PE.

Keywords: cytokines; human pregnancy; inflammatory response; placenta.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

Figures

Figure 1
Figure 1
An inflammatory response is essential in pregnancy to protect against infection, repair tissue injury, and promote a tolerogenic milieu for the fetus. An exacerbated inflammatory response can be harmful for pregnancy outcomes causing diseases such as PE.
Figure 2
Figure 2
Potential role of MIF in the pathogenesis of placental pre-eclampsia. Low MIF production in early pregnancy would contribute to the abnormal placentation with subsequent placenta hypoxia and increased production of proinflammatory cytokines, placental debris, and oxidative stress leading to pre-eclampsia.

Similar articles

Cited by

References

    1. Abalos E., Cuesta C., Grosso A.L., Chou D., Say L. Global and regional estimates of preeclampsia and eclampsia: A systematic review. Eur.J. Obs. Gynecol. Reprod. Biol. 2013;170:1–7. doi: 10.1016/j.ejogrb.2013.05.005. - DOI - PubMed
    1. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin. Perinatol. 2012;36:56–59. doi: 10.1053/j.semperi.2011.09.011. - DOI - PubMed
    1. Van Esch J.J.A., van Heijst A.F., de Haan A.F.J., van der Heijden O.W.H. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J. Matern. Fetal Neonatal Med. 2017;30:2789–2794. doi: 10.1080/14767058.2016.1263295. - DOI - PubMed
    1. Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S., Hall D.R., Warren C.E., Adoyi G., Ishaku S., et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24–43. doi: 10.1161/HYPERTENSIONAHA.117.10803. - DOI - PubMed
    1. ACOG Practice Bulletin Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obs. Gynecol. 2002;99:159–167. - PubMed

Substances